REG - Physiomics PLC - Board Changes

PhysiomicsAnnouncement

03/12/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251203:nRSC9586Ja&default-theme=true

RNS Number : 9586J  Physiomics PLC  03 December 2025

3 December 2025

 

Physiomics plc

("Physiomics" or the "Company")

 

Board Changes

 

Physiomics plc (AIM: PYC), a leading mathematical modelling, data science and
biometrics company supporting the development of new therapeutics and
personalised medicine solutions, announces that Peter Sargent will be stepping
down from his role as Executive Director and CEO of the Company to pursue
other opportunities, with effect from 29 May 2026.

The Company has commenced its search to appoint a new CEO and further
announcements will be made in due course. Dr Jim Millen, currently
Non-Executive Chairman, has confirmed that he will be available to resume the
position of Executive Chairman from the date of Dr Sargent's departure, for as
long as required to ensure business continuity in the event a suitable
replacement has not been found by that date. Dr Millen was formerly the CEO of
the Company from 2016 to 2024, during which time he grew the business from
total income of under £300k to a peak of over £900k, as well as securing a
major contract with long term client Merck KGaA and kicking off the Company's
personalised medicine initiative.

The Company expects to deliver total revenues in line with market expectations
and will be posting its interim results for the half-year ending 31 December
2025 during the first week of March 2026, in line with its usual reporting
timetable.

 

Dr Jim Millen, Non-executive Chairman of Physiomics, commented:

"Following our strategic review in early 2024, the Company has made
considerable progress on its principal growth initiatives. Pete has played an
instrumental role in achieving these objectives, contributing to notable
revenue increases and record levels of contract wins over the past two years.
We are excited for the next stage in Physiomics' growth and at the same time
wish Pete all the very best and thank him for enabling us to start the current
financial year ending 30 June 2026 with a record level of contracted projects,
a new biometrics service-line already generating revenue, and significant
progress across our personalised medicine dosing software initiative."

 

 

For more information about Physiomics and its services, please visit
www.physiomics.co.uk (http://www.physiomics.co.uk) .

 

Enquiries:

 

Physiomics plc

Dr Peter Sargent, CEO

+44 (0)1235 841575

 

Hybridan LLP (Broker)

Claire Louise Noyce

+44 (0) 203 764 2341

 

Strand Hanson Ltd (NOMAD)

James Dance & James Bellman

+44 (0)20 7409 3494

 

 

Notes to Editor

 

About Physiomics

 

Physiomics plc combines expertise across Modelling & Simulation,
Biostatistics, Data Science and Bioinformatics, together with deep biology
expertise, to help biotech and pharma companies streamline their drug
development journeys. Our approach is to help derive insight from all relevant
and often disparate data in order to de-risk decision making and optimise
research design across discovery, pre-clinical and clinical studies. Through
use of cutting-edge computational tools, bespoke models and our proprietary
Virtual Tumour technology, the Physiomics team has informed the development of
over 100 commercial projects, with over 140 targets and drugs modelled.
Clients include Merck KGaA, Astellas, Bicycle Therapeutics, Numab Therapeutics
& CRUK. 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOAZZMGZNZFGKZM



            Copyright 2019 Regulatory News Service, all rights reserved